FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a modified oligonucleotide for reducing Tau expression and a composition for treating a Tau-associated disease, disorder or condition. In one embodiment, the modified oligonucleotide consists of 12–50 linked nucleosides and the sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID No: 1.
EFFECT: invention extends the range of agents for reducing Tau expression.
21 cl, 59 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR MODULATING TAU PROTEIN EXPRESSION | 2014 |
|
RU2735551C2 |
| COMPOUND FOR MODULATION OF C9ORF72 GENE EXPRESSION AND USE THEREOF | 2013 |
|
RU2730677C2 |
| NUCLEIC ACID MOLECULES FOR REDUCING THE LEVEL OF PAPD5 OR PAPD7 MRNA FOR TREATING INFECTIOUS HEPATITIS B | 2017 |
|
RU2768699C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2747734C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2777570C2 |
| COMPOSITION FOR MODULATION OF C90RF72 EXPRESSION | 2014 |
|
RU2748426C2 |
| MODULATION OF PREKALLIKREIN (PKK) EXPRESSION | 2014 |
|
RU2712559C2 |
| OLIGONUCLEOTIDES FOR REDUCING EXPRESSION OF PD-L1 | 2017 |
|
RU2835926C1 |
| COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2015 |
|
RU2734658C2 |
| MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
